Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Author information

  • 1Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: bgartrel@montefiore.org.
  • 2Academic Unit of Clinical Oncology, Weston Park Hospital, CR-UK/YCR Sheffield Cancer Research Centre, Sheffield, UK.
  • 3Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
  • 4Department of Urology, University Hospital Charité, Berlin, Germany.
  • 5Division of Urology, Centre Hospitalier de l'Université de Montréal, CRCHUM, Montréal, QC, Canada.
  • 6Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.
  • 7Tisch Cancer Center Institute, Mount Sinai School of Medicine, New York, NY, USA.

Abstract

CONTEXT:

Advanced prostate cancer (PCa) is associated with skeletal complications, both as a result of bone metastases and because of fractures associated with fragility due to androgen-deprivation therapy (ADT). Osteoclast inhibitors are commonly used to reduce skeletal complications but are associated with a number of potential adverse events.

OBJECTIVE:

To review clinical trials of osteoclast inhibitors in advanced PCa, to discuss the adverse event profile of these agents, and to discuss strategies to address specific adverse events.

EVIDENCE ACQUISITION:

PubMed was searched for reports of clinical trials of osteoclast inhibitors in advanced PCa. As zoledronic acid and denosumab are used most commonly in this disease, these trials were the focus. The literature was reviewed to identify key publications addressing the prevention and management of adverse events associated with these drugs.

EVIDENCE SYNTHESIS:

The major findings of the trials and the adverse events are discussed. Prevention and management of common adverse events are addressed.

CONCLUSIONS:

Zoledronic acid prevents loss of bone mineral density associated with ADT and delays skeletal-related events in metastatic castration-resistant PCa (mCRPC). Denosumab reduces the incidence of fragility fractures associated with ADT, delays the onset of bone metastases in nonmetastatic castration-resistant disease, and is superior to zoledronic acid in the prevention of skeletal complications in mCRPC. Adverse events associated with both agents include osteonecrosis of the jaw and hypocalcemia. Hypocalcemia is more common with denosumab. Zoledronic acid requires dose modifications for renal insufficiency, is contraindicated in severe renal insufficiency, and has been associated with deterioration of renal function. Appropriate patient selection with close attention to dental health, supplementation with calcium and vitamin D, and monitoring of laboratory values are effective strategies to minimize the impact of adverse events associated with osteoclast inhibitors in advanced PCa.

Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

KEYWORDS:

Adverse events; Bisphosphonates; Bone-targeted agents; Denosumab; Prostate cancer; Systematic review

PMID:
23706567
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk